Key result
Coprescribing NSAIDs with OACs is linked to ~200% higher GI bleeding risk and increased strokes.
Why the study?
To evaluate the risk of GI bleeding, major bleeding, stroke, and systemic embolism associated with coprescribing NSAIDs to adults receiving oral anticoagulant therapy.
Does coprescribing nonsteroidal anti-inflammatory drugs with oral anticoagulants increase the risk of major bleeding, stroke, and systemic embolism in adults?
Cohort (n=6,354)
Yes
Does coprescribing nonsteroidal anti-inflammatory drugs with oral anticoagulants increase the risk of major bleeding, stroke, and systemic embolism in adults?
Answers are grounded in this paper and cite their sources.
Coprescribing NSAIDs with oral anticoagulants significantly increases the risk of major bleeding and stroke, highlighting the need to avoid this hazardous combination in primary care.
AIMS: To examine the risk of gastrointestinal (GI) bleeding, major bleeding, stroke and systemic embolism associated with prescribing nonsteroidal anti-inflammatory drugs (NSAIDs) to adults receiving oral anticoagulant (OAC) therapy. METHODS: We conducted a population-based cohort study in adults receiving OAC therapy using linked primary care (Clinical Practice Research Datalink GOLD) and hospital (Hospital Episodes Statistics) electronic health records. We used cause-specific Cox regression models with time-dependent NSAID treatment in a propensity score matched population to estimate the increased risk of GI bleeding, stroke, major bleeding and systemic embolism associated with NSAID use. RESULTS: The matched cohort contained 3177 patients with OAC therapy alone and 3177 with at least 1 concomitant NSAID prescription. Compared with OAC therapy alone, concomitant prescription of NSAIDs with OACs was associated with increased risk of GI bleeding (hazard ratio [HR] 3.01, 95% confidence interval [CI] 1.63 to 5.55), stroke (HR 2.71, 95% CI 1.48 to 4.96) and major bleeding (HR 2.77, 95% CI 1.84 to 4.19). The association with systemic embolism did not reach statistical significance (HR 3.02, 95% CI 0.82 to 11.07). Sensitivity analyses indicated that the results were robust to changes in exclusion criteria and the choice of potential confounding variables. CONCLUSION: When OACs are coprescribed with NSAIDs, the risk of adverse bleeding events increases and, simultaneously, the protective effect of OACs to prevent strokes reduces. There is a need for interventions that reduce hazardous prescribing of NSAIDs in people receiving OAC therapy.
No takes yet. Share an insight, caveat, or question.
Penner et al. (2022) conducted a cohort in Patients receiving oral anticoagulant therapy (n=6,354). Nonsteroidal anti-inflammatory drugs (NSAIDs) vs. No NSAID use (oral anticoagulant therapy alone) was evaluated on Gastrointestinal (GI) bleeding (HR 3.01, 95% CI 1.63 to 5.55). Coprescribing NSAIDs with oral anticoagulants increased the risk of gastrointestinal bleeding (HR 3.01) and stroke (HR 2.71) compared to oral anticoagulant therapy alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: